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The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and
treatment of VTE in cancer patients is imperative. Typically, the mainstay regimen for VTE prevention and treatment has been
anticoagulation therapy, unless contraindicated. This therapy consists of unfractionated heparin (UFH), low-molecular-weight
heparin (LMWH), factor Xa inhibitor, or vitamin K antagonist (VKA). Current guidelines recommend LMWH over VKA for the
treatment of VTE in cancer patients. Factor-speciﬁc anticoagulants have been proven safe and eﬀective, and recently factor Xa
inhibitors have emerged as a treatment alternative to heparins and VKA. Currently, three factor Xa inhibitors have been identiﬁed:
fondaparinux (the only one approved so far by the US Food and Drug Administration), idraparinux (in clinical trials), and
idrabiotaparinux (in clinical trials). This paper will examine the role of these agents, focusing on fondaparinux, for the prevention
and treatment of VTE in cancer patients.
1.Introduction
The association between cancer and venous thromboem-
bolism (VTE) has been well recognized and established [1].
Cancer patients have a 4-fold higher risk of developing VTE
thandopatientswithoutcancer,andchemotherapyincreases
that risk to 6-fold [2]. In cancer patients undergoing surgical
procedures, rates of postoperative VTE can increase 2-fold
greater than rates of postoperative VTE in patients without
cancer [3]. Frequency of VTE has increased by up to 28% in
years 1995 to 2003 in hospitalized cancer patients and with
the higher mortality rates compared to those hospitalized
cancer patients without VTE (16.3% versus 6.3%, P<
0.0001) [4].
Given that the 1-year survival rate in cancer patients with
VTE is much lower than in cancer patients without VTE
(12% versus 36%), appropriate and eﬀective thrombopro-
phylaxis—both pharmacologic and nonpharmacologic—is
imperative [9]. Eﬀective thromboprophylaxis can minimize
mortality and morbidity, potentially aﬀect survival, and
lower health-care costs associated with VTE.
The National Comprehensive Cancer Network (NCCN),
the American Society of Clinical Oncology (ASCO), and
recently the American College of Chest Physicians (ACCP)
have published guidelines for the prevention and treatment
of VTE in cancer patients (Table 1). These guidelines recom-
mend using unfractionated heparin (UFH), low-molecular-
weight heparins (LMWHs), and, recently, direct factor Xa
inhibitors for the prevention of VTE in cancer patients who
are hospitalized [5–8].
Currently, prophylaxis for catheter-related thrombosis
is not recommended owing to conﬂicting evidence and a
lack of major clinical trials [10]. For treatment of VTE in
cancer patients, guidelines recommend LMWH as ﬁrst-line
therapy and vitamin K antagonist (VKA) as second-line
therapy. The recommended duration of treatment ranges2 Advances in Hematology
Table 1: Summary of guidelines for prevention and treatment of venous thromboembolism in cancer [5–8].
Guidelines and pharmacologic prophylaxis VKA UFH LMWH FXa-I
American College of Chest Physicians (ACCP)
No Yes (SQ) Yes Yes
(Prevention in cancer patients (medical and surgical))
Duration of prevention: (1) For medical oncology cancer patients who have acute medical illness or who are bedridden for the
duration of hospitalization. (2) For surgical cancer patients (pelvic, abdominal, orthopedic) duration of prophylaxis up to 4 weeks.
(3) In the presence of contraindications or high risk of bleeding, mechanical methods may be temporarily substituted and
pharmacologic prophylaxis should resume after risk of bleeding subsides.
American College of Chest Physician(ACCP) Acute No No Yes Not addressed
(Treatment in cancer patients) Long term Yes No Yes No
Duration of treatment: At least 3 months of treatment with LMWH, followed by treatment with either LMWH or VKA.
American Society of Clinical Oncology (ASCO)
No Yes (SQ) Yes Yes
(Prevention in cancer patients)
Duration of prevention: (1) For as long as the patient is hospitalized (due to surgery or acute medical illness) or until the patient is
ambulatory. (2) In the presence of contraindication or high risk of bleeding, mechanical methods may be temporarily substituted and
pharmacologic prophylaxis should resume after risk of bleeding subsides. (3) In certain multiple myeloma patients receiving
thrombogenic chemotherapy (lenalidomide or thalidomide with dexamethasone), low-dose VKA (INR∼1.5) or enoxaparin (40mg)
may be considered.
American Society of Clinical Oncology (ASCO) Acute 5–10 days No Yes (IV) Yes Yes
(Treatment in cancer patients) Long term Yes No Yes Not addressed
Duration of treatment: LMWH is preferred for 5–10 days, then LMWH for at least 6 months. VKA may be substituted if LMWH is
not accessible. After 6 months of treatment, indeﬁnite treatment duration for cancer patients with metastasis or those actively
receiving chemotherapy.
National Comprehensive Cancer Network (NCCN)
Yes Yes (SQ) Yes Yes
(Prevention in cancer patients)
Duration of prevention: (1) For the duration of hospitalization for medical illness and up to 4 weeks in surgical cancer patients. (2) In
the presence of contraindication, use mechanical prophylaxis until bleeding risk subsides. (3) In certain high-risk medical oncology
patients (i.e., aggressive tumor such as pancreatic, gastric, lymphoma, or in cases of obesity or prior VTE), longer prophylaxis is
recommended. (4) In certain multiple myeloma patients receiving thrombogenic chemotherapy (lenalidomide or thalidomide with
dexamethasone), VKA (INR of 2-3) or aspirin (81–325mg) may be considered.
National Comprehensive Cancer Network (NCCN) Acute 5–10 days No Yes (IV) Yes Yes
(Treatment in cancer patients) Long term Yes No Yes Not addressed
Duration of treatment: (1) LMWH is preferred for the ﬁrst 3–6 months in DVT and 6–12 months in PE. (2) VKA can be considered if
LMWH is not accessible.
VKA: vitamin K antagonist; UHF: unfractionated heparin; LMWH: low-molecular-weight heparin; FXa-I: direct factor-Xa inhibitor; SQ: subcutaneous; IV:
intravenous; INR: international normalized ratio; DTV: deep vein thrombosis.
from 3 to 12 months, depending on which set of guidelines is
followed. For long-term treatment of VTE in cancer patients,
guidelines do not address the role of factor Xa inhibitors [5–
8].
Factor-speciﬁc anticoagulants have been proven safe and
eﬀective, and, recently, factor Xa inhibitors have emerged as
an alternative therapy for VTE in cancer patients. In this
paper, we examine the role of injectable factor Xa inhibitors
in cancer patients, focusing on fondaparinux, the only such
agentyetapprovedbytheUSFoodandDrugAdministration
(FDA). The paper covers clinical pharmacology, clinical
pharmacokinetics, and available data from clinical trials in
cancer patients. We also addressed the safety of using factor
Xa inhibitors for the prevention and long-term treatment
of VTE in special populations of cancer patients, such as
patients who are obese, have renal insuﬃciency, or have
a high risk of bleeding. Finally, we presented recent and
emerging data on idraparinux and idrabiotaparinux, two
factor Xa inhibitors currently being investigated in clinical
trials for the prevention and treatment of VTE in cancer
patients.
2.Fondaparinux
2.1. Pharmacodynamic Proﬁle of Indirect Factor Xa Inhibitor.
After activation of the coagulation cascade by either the
intrinsic or extrinsic pathways, the generation of factor Xa is
ampliﬁed. Factor Xa is the ﬁrst step in the common pathway
that leads to the generation of thrombin which converts
prothrombin to thrombin and ﬁnally the formation of the
ﬁbrin (Figure 1)[ 11]. Brieﬂy, VKAs inhibit the formation of
factors II, VII, IX, X and the natural anticoagulant proteins
Ca n dS[ 12]. UFH and LMWHs have more speciﬁcity for
inhibition of coagulation factors such as factor Xa and factor
IIa. LMWH has been shown to bind mostly to factor Xa andAdvances in Hematology 3
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Figure 1: Mechanism of action of anticoagulants. Abbreviations: vitamin k antagonist (VKA); low-molecular-weight heparin (LMWH);
unfractioned heparin (UFH).
minimally to factor IIa through activation of antithrombin
(AT) III (ATIII) [12].
In recent years, more targeted anticoagulants such as
fondaparinux (1728 Da or pentasaccharides) have emerged
that speciﬁcally target factor Xa. Fondaparinux does not
inhibit factor IIa since more than18 monosaccharides are
required for simultaneous binding to AT and factor IIa
[13]. Fondaparinux binds reversibly to AT in a 1:1 ratio
through a noncovalent bond, which causes conformational
changeandthenselectivelyandrapidlyinhibitsfactorXaand
thereby inhibition of thrombin (inhibition of 1 unit of factor
Xa results in ∼50 units lower concentration of thrombin).
Fondaparinux binding toATcausesanapproximate 300-fold
increase in the rate at which AT inhibits factor Xa [14, 15].
Direct factor Xa inhibitors inhibit free factor Xa and bound
factor Xa in the prothrombinase complex, whereas indirect
factor Xa (fondaparinux) inhibitors target factor Xa through
AT.FactorXainhibitorscanblocktheformationofthrombin
rather than the inhibition of thrombin activity [16].
Currently, there are three injectable indirect factor Xa
inhibitors in various stages of development: fondaparinux,
idraparinux, and idrabiotaparinux (Table 2). Only fonda-
parinux has been approved by the FDA for the prevention
and treatment of VTE [17, 18].
Presently, there are oral formulations of direct factor Xa
inhibitors, but these are beyond the scope of this paper; oral
factorXainhibitorsthatareinvariousphasesofclinicaltrials
include rivaroxaban (Xarelto), which has been approved
in Europe for prevention of VTE, apixaban, edoxaban,
betrixaban, eribaxaban, TAK-442, LY517717, YM150, DU-
176b, and PRT-054021 [19].
2.2. Pharmacokinetic Proﬁle. Fondaparinux exhibits the fol-
lowing pharmacokinetic parameters: complete bioavailabil-
ity of ∼100%; peak plasma concentration of 0.34mg/L (dose
of 2.5mg); time-to-peak plasma concentration of 1.7 hours;
linear pharmacokinetics in the 2mg to 8mg dose range.
Fondaparinux is excreted via the kidneys (64% to 74%) with
a terminal half-life (Tβ1/2)o f∼17 hours [20]. Fondaparinux
is not metabolized by the cytochrome P450 (CYP)enzyme in
the liver [15].The volume of distribution (Vd) and protein
binding of fondaparinux is estimated to be from 7L to
11L and >97%, respectively; hence, fondaparinux does not
distribute to extravascular space such as adipose tissue.
Fondaparinux has a negligible nonspeciﬁc binding to α-1-
acid-glycoprotein [15].
Pharmacokinetic studies have produced peak and trough
levels of fondaparinux at steady state (Css max/min)o f0 . 3 9t o
0.50mcg/mL and 0.14 to 0.19mcg/mL for the 2.5-mg dosing
schedule,respectively.Thepeakandtroughlevels(orranges)
of fondaparinux at Css max/min for the 5-mg, 7.5-mg, and 10-
mg dosing schedules are 1.20 to 1.26mcg/mL and 0.46 to
0.62mcg/mL [18].4 Advances in Hematology
Table 2: Injectable factor Xa inhibitors [17, 18].
Fondaparinux
Idraparinux Idrabiotaparinux
Target
Factor Xa
Factor Xa Factor Xa
Route of administration
Subcutaneous
Subcutaneous Subcutaneous
Prevention dose
2.5 mg
Not available Not available
Dosing schedule
Daily
Weekly Weekly
Therapeutic dose
Acute VTE in conjunction with VKA:
(ASCO) + (NCCN)
50kg: 5mg once daily; 50–100kg: 7.5mg once daily;
>100kg: 10mg once daily
2.5mg 3.0mg
Bioavailability (%)
100
100 100
Half-life (t1/2)
17 hours
60 days 60 days
Elimination
Renal
Renal Renal
Antidote
None
None Avidin
Market status/FDA approval
FDA approved for prevention and treatment of venous
thromboembolism In clinical trials In clinical trials
Contraindication
(i) Patients with active bleeding
(ii) Bacterial endocarditis
(iii) Thrombocytopenia
associated with positive
antiplatelet antibodies
(i) Patients with CrCl
<30mL/min
(ii) Neuraxial anesthesia
(iii) Weight < 50kg
(prophylactic doses)
Not available Not available
Monitoring parameters
Monitor hemoglobin, platelets
Not available Not available
VTE: venous thromboembolism; VKA: vitamin K antagonist; ASCO: American Society of Clinical Oncology; NCCN: National Comprehensive Cancer
Network; FDA: US Food and Drug Administration; CrCl: creatinine clearance.
2.3. Comparative Eﬃcacy in VTE Prevention Trials. Primary
data using fondaparinux for prevention of VTE in cancer
patient is clearly lacking. In a study of elderly patients
(number (n) = 849) with acute medical illnesses (∼15%
had cancer), patients who received fondaparinux (2.5mg per
day per day for 14 days) had a relative risk reduction (RRR)
of 46% (95% conﬁdence interval (CI): 7.7% to 69.3%) in
VTEcomparedwithpatientswhoreceivedtheplacebo(5.6%
versus 10.5%). The patients who received fondaparinux
had a 0.4% incidence of major bleeding, and their 32-day
mortality rate was 3.3%, while patients who received the
placebo had a 32-day mortality rate of 6.0% (P = 0.006).
In this study, fondaparinux provided the same eﬃcacy across
body weight ranges of 32kg to 111kg, and bleeding was not
related to body weight [21].
Turpie et al. showed a VTE rate reduction of 69.8%
in patients who underwent major abdominal surgery (40%
of patients had surgery for cancer); patients received either
fondaparinux (2.5mg per day or prophylactic dose) plus
intermittent pneumatic compression (IPC) or IPC alone,
with low major bleeding rates of 1.6% bleeding rate in
the fondaparinux plus IPC group and the 0.2% in the
IPC alone group (P = 0.006) [22]. The ﬁrst injection of
fondaparinux was given 6 to 8 hours after surgical closure,
and the second injection of fondaparinux was given 16
to 28 hours after the ﬁrst injection; an epidural, if used,
was removed 2 hours prior to the ﬁrst injection. In this
study, the eﬃcacy of fondaparinux was proven irrespective
of age, gender, weight (mean, 82kg), or type and duration
of surgery. The overall mortality rate was 1.3% in the
fondaparinux plus IPC group (1 fatal pulmonary embolism
(PE)) and 0.8% in the IPC group (1 fatal PE, P = 0.42)
[22].
In another study of VTE prevention in surgery patients,
Agnelli et al. evaluated a subset of cancer patients (n = 954)
who underwent major abdominal surgery and demonstrated
that rate of VTE in patients who received fondaparinux
(2.5mg per day) was 4.7% whereas the rate of VTE in
patients who received dalteparin (5000 units per day) was
7.7%; the RRR was 38.6 % (95% CI: 6.7% to 59.7%), and
the incidence rate of major bleeding was 3.4% versus 2.5%
(P = 0.355) [23]. Major bleeding occurred in 2.8% of
patients who received their ﬁrst fondaparinux injection at
least 6 hours after surgery closure and in 3.4% of patientsAdvances in Hematology 5
who received their ﬁrst fondaparinux dose within 6 hours of
surgery closure [23].
Overall, these studies suggest that fondaparinux could be
an option for prevention of VTE in cancer patients who are
hospitalized for either an acute medical illness or a surgical
procedure.
2.4. Comparative Eﬃcacy in VTE Treatment Trials. Primary
data of fondaparinux for treatment of VTE cancer patients
is also lacking. Two studies have shown the similar eﬃcacy
of fondaparinux versus LMWH and VKA for the initial
phase of VTE treatment that enrolled 10% of patients with
cancer [24, 25]. A subgroup analysis of cancer patients in
the Matisse-DVT trial showed that recurrent VTE rates in
the initial treatment period, for the entire study period,
and in patients with advanced cancer were as follows for
the fondaparinux group versus the enoxaparin group: 2.4%
versus 0.0%, for an absolute diﬀerence of 2.4% (95% CI:
−0.3% to 5.0%, P = 0.080); 12.7% versus 5.4%, for an
absolute diﬀerence of 7.3% (95% CI: 0.1% to 14.5%, P =
0.046); 11.5% versus 3.7%, foran absolute diﬀerence of 7.8%
(95% CI: −6.4% to 22.0%, P = 0.28). Major bleeding rates
in cancer patients during the entire study period were 7.1%
in the fondaparinux group versus 7.2% in the enoxaparin
group, for an absolute diﬀerence of −0.1% (95% CI: −6.7%
to 6.5%, P = 0.99). Mortality rates were 18.3% in the
fondaparinux group versus 15.3% in the enoxaparin group,
for an absolute diﬀerence of 2.9% (95% CI: 6.6% to 12.4%).
Thissubgroupanalysisofcancerpatientsshowedthatduring
the entire study period there was a trend toward higher rates
of recurrent VTE in fondaparinux-treated patients (12.7%
in the fondaparinux group versus 5.4% in the enoxaparin
group; P = 0.046) [26]. One possible explanation for the
higher rates of recurrent VTE in the fondaparinux group
could be that 8.7% of the fondaparinux-treated patients
(bridged with VKA) had an international normalized ratio
(INR) <2.0 (at the time of recurrent DVT versus 1.8%
of the enoxaparin-treated patients; 3.6% of patients in the
enoxaparin group had therapeutic INRs (2.0 to 3.0) versus
1.6% of patients in the fondaparinux group [27].
A subgroup analysis of cancer patients in the Matisse-PE
study reported that recurrent VTEs in the initial treatment
period, for the entire study period, and in patients with
advanced cancer were as follows for the fondaparinux group
versus the UFH group: 0.9% versus 3.9%, for an absolute
diﬀerence of −3.0% (95% CI: −6.8% to 0.8%, P = 0.12);
8.9%versus17.4%,foranabsolutediﬀerenceof −8.3%(95%
CI: −16.7% to 0.1%, P = 0.054); 16.0% versus 29.0%,
for an absolute diﬀerence of −13.0% (95% CI: −35.0%
to 8.5%, P = 0.24), respectively. Major bleeding rates in
cancer patients during the entire period were 3.6% in the
fondaparinux group versus 6.3% in the UFH group, for
an absolute diﬀerence of −2.7% (95% CI: −8.1% to 2.7%,
P = 0.33). Mortality rates during the 3-month followup
were 25.0% in the fondaparinux group versus 18.8% in the
UFH group, for an absolute diﬀerence of 6.2% (95% CI:
−4.2% to 16.7%). In this subgroup analysis, higher rates of
recurrent VTE during the entire study were observed in the
UFH group compared with the fondaparinux group (17.2%
versus8.9%,P = 0.054).PatientsrandomizedtoreceiveUFH
plus VKA had lower INR rates at the time of VTE recurrence
thandid patients inthefondaparinuxgroup, 7.0%and2.7%,
respectively, for an absolute diﬀerence of 0.4% (95% CI:
−10.0% to 1.0%) [27].
2.5. Dosing of Fondaparinux
2.5.1.DosingofFondaparinuxinUnderweightandOverweight
Patients with Cancer. Fondaparinux is dosed according to
the patient’s body weight based on the following schema: for
ab o d yw e i g h to f<50kg, the dose is 5mg subcutaneously
(SQ) daily; for a body weight of 50kg to 100kg, the dose is
7 . 5m gS Qd a i l y;f o rab o d yw e i gh t>100kg, the dose is 10mg
SQ daily [18].
Pooled analysis of the eﬀect of obesity (cutoﬀ,3 0k g / m 2)
onoutcomesintheMatissetrials(Matisse-DVTandMatisse-
P E )h a sb e e nr e p o r t e d .B o d yw e i g h t( k g )a n db o d ym a s s
index (BMI; kg/m2) ranges reported in this analysis were
from 33kg to 216 kg and from 12.8kg/m2 to 8.1kg/m2,
respectively [28]. When investigators analyzed the data from
the Matisse trials, they observed no diﬀerence in recurrent
VTE rates between fondaparinux and heparins (enoxaparin
or UFH) across body weight and BMI categories as follows:
body weight ≤100kg (3.90% versus 4.45%, P = 0.42);
body weight >100kg (4.0% versus 5.7%, P = 0.41); BMI
<30kg/m2 (3.9% versus 4.5%, P = 0.42); BMI ≥30kg/m2
(3.7% versus 4.8%, P = 0.40). Bleeding rates did not
diﬀer between fondaparinux and heparins (enoxaparin or
UFH): body weight ≤100kg (1.3% versus 1.2%, P = 0.77);
body weight >100kg (0.4% versus 0.8%, P = 0.62); BMI
<30kg/m2 (1.5% versus 1.2%, P = 0.53); BMI ≥30kg/m2
(0.3% versus 1.1%) [28]. The results of this study showed
that the safety and eﬃcacy of fondaparinux for initial
treatmentof VTEwascomparabletoheparin acrossdiﬀerent
body weight and BMI categories [28]. In the Matisse trials,
cancer patients comprised 25% of total patients enrolled
overall [24, 25]. Until further evidence is available in cancer
patients with extremes of body weight and BMI, data
presented by the pool analysis should be interpreted with
caution.
2.5.2. Dosing of Fondaparinux in Cancer Patients with
Renal Disease. Fondaparinux is excreted via the kidneys,
is contraindicated in patients with CrCl <30mL/min, and
should be used with caution in patients with CrCl from
30 to 50mL/min [18]. Close attention to estimation of the
glomerular ﬁltration rate (GFR) is imperative in dosing
of antithrombotics such as fondaparinux that has a long
t1/2.
Estimation of the GFR calculated with the Cockcroft-
Gault (CG) formula diﬀe r sw i d e l yf r o mc a l c u l a t i o n sm a d e
with the Modiﬁcation of Diet in Renal Disease (MDRD)
formula in low BMIs and in patients older than 75 years
[29]. Another study reported higher rates of bleeding and
transfusions in patient with acute coronary syndrome that
were prescribed unadjusted doses of antithrombotics based
on CG [30].6 Advances in Hematology
The CG formula may better assess GFR in patients with
normal serum creatinine (Scr) levels who are at risk of
developingkidneydiseasesuchaspatientswhohavediabetes,
who have stage 1 or 2 CKD, or who are elderly. The MDRD
formula may be more appropriate for predicting the GFR in
patients with CKD who do not have normal Scr levels, who
have a GFR <30mL/min, and who have a high BMI. Neither
CG nor MDRD was accurate in the following patients: heart
transplant patients, kidney donors, patients with advanced
liver disease, and hospitalized patients [26].
In a pharmacokinetic simulation study, Turpie et al.
showed that dosing fondaparinux at 1.5mg and 2.5mg SQ
daily provided comparable trough plasma concentration
(Cmin), peak plasma concentration (Cmax), and area under
the curve (AUC0–24h) at days 1, 7, and 28 in patients with a
CrCl of ≥20mL/min, <50mL/min, and CrCl >50mL/min.
However, dosing fondaparinux at 2.5mg produced much
higher Cmin,Cmax,a n dA U C 0–24h in patients with20mL/min
≥ CrCl < 50mL/min [31]. The fondaparinux 1.5-mg dosing
schedule may be a safe and eﬀective alternative to 2.5-mg
recommended dose for the prevention of VTE; however,
determining the most eﬀective dosing schedule for fonda-
parinux requires further trials and investigation.
Results from studies of fondaparinux (2.5mg) used as an
anticoagulantduringhemodialysishaveshowntheeﬃcacyof
fondaparinux in preventing circuit clotting during dialysis;
however, anti-Xa activity is increased and may potentially
increase the risk of bleeding in such patients on dialysis
[32, 33].
To our knowledge, there have been no studies assessing
the safety and eﬃcacy of fondaparinux in patients with end-
stage renal disease and concomitant VTE. Dialysis patients
with an acute medical illness who are hospitalized should
receive prophylaxis with UFH [34].
2.6. Monitoring Anti-Xa Levels in Patients Receiving Fonda-
parinux. Currently, to our knowledge, there have been no
clinical trials to validate peaks and troughs in the eﬃcacy of
fondaparinux.
Fondaparinux-speciﬁc anti-Xa assay should be used to
monitor the anti-Xa levels of fondaparinux in patients who
have unstable renal function, are elderly, are morbidly obese,
or have a low BMI [35]. Activated partial thromboplastin
time (aPTT) and prothrombin time (PT) cannot be used to
measure anticoagulant properties of fondaparinux because
these test systems measure the inhibition of thrombin and
not factor Xa [36]. Fondaparinux has been shown to aﬀect
the protein S assay in vitro, resulting in false elevation of
protein S levels; however, the signiﬁcance of these ﬁndings
is yet to be determined [37]. Linkins et al. have shown that
fondaparinux has no eﬀect on aPTT or activated clotting
time (ACT), contrary to heparins; therefore, such tests are
insensitive to the anticoagulant properties of fondaparinux
[38]. Smogorzewska et al. showed that fondaparinux (pro-
phylactic or therapeutic dose) prolonged PT by 1 second and
the aPTT by 4 to 5 seconds without signiﬁcant changes in
ﬁbrinogen, AT, and thrombin time assays [39]. Depasse et
al. showed that LMWH anti-Xa (IU/mL) levels varied signif-
icantly between diﬀerent assays for the same fondaparinux
concentrations(P<0.01)[40].Methodologyofdetermining
factor Xa activity of fondaparinux requires a chromogenic
assay that is calibrated to fondaparinux but not to LMWH
or UFH.
2.7. The Role of Fondaparinux in Critically Ill Cancer Patients.
Despite prophylaxis use in the intensive care unit (ICU),
the rate of DVT is about 5.1% to 5.8% and the rate of
PE is about 1.2% to 2.3%, the major bleeding rate is
approximately 13.0%, and the mortality rate is 15.0% [41].
The pharmacokinetic properties of drugs in ICU patients
may be altered owing to reduced hepatic metabolism,
reduced transport function, intestinal atrophy, increased or
decreased extravascular ﬂuids, reduced CrCl, altered tissue
permeability, or decreased protein binding of the drugs [42].
Administration of vasopressors to patients who received
fondaparinux (2.5mg) did not change the mean range of
anti-Xa levels compared with those without vasopressors
(0.2 to 0.4IU/mL versus 0.3 to 0.2IU/mL, P = 0.06).
Interestingly, investigators found no occurrence VTE and
2 minor bleeds with anti-Xa of 0.24 and 0.44IU/mL
[43].
There are currently no guidelines for dose adjustment of
fondaparinuxbasedonanti-Xalevels,and,toourknowledge,
no studies have compared the eﬀectiveness of fondaparinux
versus heparin in ICU patients. Use of pharmacological
agents for DVT prophylaxis in ICU patients should be based
on evidence, the half-life of the agent, and the availability of
an antidote if bleeding occurs.
2.8. Role of Fondaparinux in Cancer Patients with Heparin-
Induced Thrombocytopenia. Heparin-induced thrombocy-
topenia (HIT) is an immune-mediated disorder caused by
immunoglobulin G (IgG) antibodies that bind to platelet
factor 4 (PF4), resulting in the generation and release of pro-
coagulant microparticles such as thrombin [44]. Thrombin
causes disseminated arterial and venous thrombi and has a
reported absolute risk of thrombosis of 35% to 57% in some
clinicalsettings[45].MortalityratesinpatientswithHITand
thrombosis can be as high as 30%, and 20% of patients who
survive require a limb amputation [46].
Patients who can carry risk of HIT of >1% are surgical
patients who received UFH (prophylactic dose or treatment
dose) for more than 4 days. Patients who carry risk of HIT
of 0.1% to 1% are (1) medical patients who received UFH
(prophylacticdoseortherapeuticdose)formorethan4days;
(2) surgical patients who received LMWH for more than 4
days or heparin ﬂushes for more than 4 days; (3) medical or
surgical patients who were switched from UFH to LMWH
carryanestimated risk HITof0.1% to 1.0%. Finally,medical
or surgical patients who received LMWH for more than 4
days, medical patients received heparin ﬂushes only, or any
patients that have who received UFH or LMWH for fewer
than 4 days have a risk of HIT of 0.1% [47].
Fondaparinuxisconsideredapentasaccharideandhasan
average molecular weight of 1.7kDa and only 5 saccharide
residue. Evidence suggests that an increased risk for HIT-
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weight and length of the polysaccharides (>2.4kDa and
>10 saccharide units). Typically, in LMWHs, the range of
molecular weight and saccharide residues vary from 4.5kDa
to 7.5kDa and 13 to 15 saccharide residues, respectively. In
UFH,themolecularweightandsaccharideresiduesaremuch
higher, 15kDa and 45kDa. It has been hypothesized that the
lower saccharide residue, the lower antigenicity [48].
Testing the sera of patients from 2 clinical trials, investi-
gators showed that the PF4-fondaparinux complex, but not
thePF4-LMWHcomplex,isreadilyrecognizedbyantibodies
generated during HIT and that the risk of HIT associated
with fondaparinux is very low [49]. Kovacs reported a
successful case series of ﬁve patients with the diagnosis of
HIT who were treated with 7.5mg of fondaparinux [50]. In
this case series, time to platelet recovery was between 2 and
9 days, with no new thrombotic activity or major bleeding
[50].
Wester et al., in a retrospective study of seven critically
ill patients with suspected HIT, investigated the role of
fondaparinux at a dosing schedule of 2.5mg per day, with
dose adjustments according to renal function (adjusted to
1.5mg) [51]. HIT antibodies were absent in all patients;
ﬁve patients were classiﬁed as unlikely to have HIT, whereas
two patients were classiﬁed as possibly having HIT. During
treatment with fondaparinux, platelets recovered in ﬁve
patients but did not recover in the other two. The authors
concluded that the role of fondaparinux in cases of sus-
pected HIT might be as bridging until HIT is conﬁrmed
[51].
Several case reports in the literature have advocated the
useofatherapeuticdoseoffondaparinuxinthemanagement
of HIT [52]. Lobo et al. showed in a prospective pilot trial
comparing HIT patients treated with fondaparinux (n =
7) with historical controls treated with direct thrombin
inhibitor (DTI; n = 10) that 7 of 7 fondaparinux-treated
patients had complete platelet recovery time (increase from
baseline by at least 30% of nadir to >100,000/mm3 by day
7) and no fondaparinux-treated patients experienced new
thrombotic events, major bleeding, or death by day 30.
In the historical control group, 8 of 10 patients achieved
platelet recovery with no new thrombotic events or major
bleeding, but 4 had limb gangrene that might have been
due to inappropriate dosing of warfarin in relation to the
diagnosis of HIT [53].
NCCN guidelines considers use of fondaparinux for
treatment of HIT as unlabeled use, and the ACCP suggests
that after recovery of platelet levels during initial treatment
with DTI, the DTI can be replaced with fondaparinux in
therapeutic doses and bridging to warfarin [5, 47].
The use of fondaparinux in patients with HIT has been
challenged. In 2003, Warkentin et al. reported a platelet
serotonin-release assay of 90% (normal value, <20%) and
an anti-PF4 polyanion enzyme immunoassay of 1.871 units
(normal value, <0.40) in a patient who was not predisposed
to heparin and was postoperatively on fondaparinux (2.5-
mg dosing schedule), with a concomitant platelet drop and
signs of thrombosis. The authors indicated that in rare
cases fondaparinux can activate antibodies against PF4 that
resemble the antibodies in HIT [54].
Rota et al. reported a strong optical density (OD) of
1.700 units without thrombosis in a patient exposed to
fondaparinux after undergoing a total hip replacement.
Three years earlier, the patient had a history of HIT with
thrombosis due to nadroparin. The authors concluded that
fondaparinux should be used with caution in patients with
HIT [55].
Recently, Alsaleh et al. also reported an OD of 1.75
units (normal value, <0.45U), heparin-dependent platelet
activation at a dilution of 1 in 8 (3% release at 0U/mL,
100% at 0.1U/mL, and 0% at 100U/mL UFH), with new
DVT and concomitant thrombocytopenia in a patient on
fondaparinux prophylaxis following a surgical procedure.
The patient had been on prophylaxis with LMWH post-
operatively for 3 days. In this case, platelet activation was
also observed with pharmacological doses of enoxaparin
(0.1U/mL), but not in the presence of fondaparinux [56].
Treatment of cancer patients with HIT should not diﬀer
from treatment of patients who do not have cancer, and
treatment consists of DTIs (such as lepirudin, bivalirudin, or
argatroban) for the acute phases of HIT followed by long-
term VKA after platelet recovery [57].
Until further evidence is available from randomized
clinical trials, fondaparinux should be used with caution to
treat HIT in cancer patients.
2.9. Bleeding Risk Assessment. To date, there is no vali-
dated bleeding risk assessment in cancer patients; however,
several bleeding assessment tools have been examined in
clinical trials. Assessment of bleeding risk will enable closer
monitoring of patients who are at risk of bleeding while
on anticoagulation therapy. In one study, risk of bleeding
associated with anticoagulation in cancer patients was about
4.2% during 90 days of therapy, with a mortality rate greater
than 60% within 30 days of a major bleeding event [58].
Data for management of VTE in cancer patients with
thrombocytopenia is lacking. Transient thrombocytopenia
duetochemotherapydoublesthebleedingriskfrom10%ata
plateletcountof20,000/mm3 to20%whentheplateletcount
drops below 10,000/mm3 in solid tumor patients [59].
NCCN considers platelet counts of less than 50,000/mm3
as a contraindication to prophylactic or therapeutic anti-
coagulation therapy [5, 6]. ASCO recommends using ther-
apeutic anticoagulation in cancer patients with preexisting
thrombocytopenia with caution. Validated bleeding assess-
ment tools in the literature are evolving. The prospective
registry Registro Informatizado de La Enfermedad Throm-
boemb´ olic` a (RIETE) investigators have identiﬁed variables
such as recent major bleed, renal dysfunction, anemia,
cancer, clinically overt PE, and advanced age as being
associated with major bleeding. When RIETE investigators
assigned point scores for bleeding based on risk factors,
the incident rate of major bleeding was 0.1% for low risk,
2.8% for intermediate risk, and 6.2% for high-risk patients.
(Table 3)[ 60].
In a recent analysis of the prospective RIETE registry,
investigatorsidentiﬁedvariablessuchasage>75years,recent
major bleeding, immobility ≥4 days, metastatic cancer,
anemia, platelet count <100,000/mm3,a b n o r m a lP T ,a n d8 Advances in Hematology
Table 3: Multivariate analysis for major bleeding and bleeding risk index classiﬁcation [60, 61].
(a)
Risk factors Odds ratio (95% CI) P value Points
Recent major bleed 2.7 (1.6–4.6) < 0.001 2.0
Serum creatinine (Scr) > 1.2mg/dL 2.1 (1.7–2.8) < 0.001 1.5
Anemia 2.1 (1.7–2.7) < 0.001 1.5
Cancer 1.7 (1.4–2.2) < 0.001 1.0
Clinically overt pulmonary embolism 1.7 (1.4–2.2) < 0.001 1.0
Age > 75 years 1.7 (1.3–2.1) < 0.001 1.0
0 points = low risk.
0.1% (95% CI: 0.0–0.2).
1–4 points = intermediate risk.
2.8% (95% CI: 2.4–3.3).
>4 points= high risk.
7.3% (95% CI: 4.0–9.1).
(b)
Risk factors Odds ratio (95% CI) P value Points
Age > 75 years 2.16 (1.49–3.16) < 0.001 1.0
Recent major bleed 2.64 (1.44–4.83) 0.002 1.5
Immobility ≥ 4 days 1.99 (1.40–2.83) < 0.001 1.0
Metastatic cancer 3.80 (2.56–5.64) < 0.001 2.0
Anemia 1.54 (1.07–2.22) 0.021 1.0
Platelet count < 100.000/mm3 2.23 (1.16–4.29) 0.016 1.0
Elevated prothrombin time (PT) 2.09 (1.34–3.26) 0.001 1.0
Creatinine clearance (CrCl) < 30mL/min 2.27 (1.49–3.44) < 0.001 1.0
Distal deep vein thrombosis 0.39 (0.16–0.95) 0.038 −1.0
Score < 1.5 = low risk 0.16%.
LR = 0.29 (95% CI: 0.20–0.41).
Score 1.5–4 = intermediate risk 1.06%.
LR = 1.92 (95% CI: 1.69–2.17).
Score > 4 = high risk 4.24%.
LR = 7.95 (95% CI: 5.42–11.6).
CrCl < 30mL/min as independent risk factors for bleeding.
Then investigators composed a risk scoring system based on
assigned points to each variable to predict the risk of fatal
bleeding during 90 days following diagnosis of VTE. Patients
with a risk score of <1.5 points had a bleeding incidence
rate of 0.16%, those with a risk score of 1.5 to 4.0 had a
bleeding incidence of 1.06%, and those with score of >4.0
hada incidenceof4.24% of fatalbleeding withthelikelihood
ratio 0.29 for the low-risk group, 1.92 for the moderate-
risk group, and 7.95 for the high-risk group (Table 3)[ 61].
We recommend that patients with any of the following risk
factors for major bleeding should be closely monitored while
on anticoagulation: age (>75 years), presence of metastatic
cancer, immobility, platelet count <100,000/mm3,a n e m i a ,
recent major bleed, coagulopathy, and CrCl < 30mL/min.
2.10. Reversal of Fondaparinux. As described before, the
incidence of bleeding associated with fondaparinux ranges
from 1.1% to 7.2% [27, 28].
Following the assessment of bleeding risk, choosing
long-acting anticoagulants requires adequate reversibility by
an antidote in cases of bleeding. VKAs can be reversed
with administration of vitamin K, LMWH can be partially
reversedwiththeadministration ofprotamine,andUFHcan
be completely reversed with administration of protamine; in
bleeding events, transfusion of red blood cells is required as
well [62].
There is limited experience with reversal of fondaparinux
inbleedingcases,and,todate,therearenostudiesconducted
speciﬁcally in cancer patients. There are case reports and
limitedlaboratorystudiesalludingtojudicioususeofrecom-
binant factor VIIa (rVIIa) for reversal of bleeding associated
with fondaparinux. rVIIa is an activated factor VIIa that is
approved for use in cases of congenital factor VII deﬁciency,
patients with factor VIII or IX inhibitors, and cases of
Glanzmann thrombasthenia; however, in recent years, it has
beenused“oﬀ-label”forreversalofwarfarin,centralnervous
system bleeding, uremia, bone marrow transplantation, type
III von Willebrand disease, factor XI deﬁciency, Jehovah’s
Witness hematologic malignancies, liver disease (cirrhosis,
liver transplantation, or fulminant hepatic failure), and
in platelet disorders (quantitative and qualitative). rVIIa
primarily binds to TF following injury to the vessel wall
and activates factor X to factor Xa, leading to conversion
of prothrombin to thrombin. Thrombin activates platelets,
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andﬁnallyactivatesthrombin-activableﬁbrinolysisinhibitor
(TAFI), which downregulates ﬁbrinolysis. The usual dose if
rVIIa is 90μg/kg administered intravenously [63].
In a randomized, placebo-controlled study of 16 healthy
male subjects who received a single dose of fondaparinux
(10mg), the eﬀect of a single dose of 90μ/kg intravenous
(IV) bolus of rFVIIa was studied on coagulation parameters.
Thrombin generation time (TGT) was rapidly normalized
by administration of rFVIIa and persisted for 6 hours
(P<0.001). The endogenous thrombin potential (ETP)
at 2 and 8 hours was 9% higher in the fondaparinux plus
rVIIa than in the fondaparinux group alone (P = 0.056).
Prothrombin activation was increased by 34% at 2 and 8
hours in the fondaparinux plus rVIIa compared with the
fondaparinux group alone (P = 0.022). The AUC analysis
between time points 2 and 8 hours showed a signiﬁcant
reduction in the aPTT (P = 0.015). The PT was reduced
26% after the administration of rVIIa (14.3 ± 0.9t o9 .2 ±
0.9 seconds; P<0.0001). The authors concluded that
administration of rFVIIa as a single 90μ/kg IV bolus could
neutralize the anticoagulant eﬀect of fondaparinux (10mg)
[64].
Theeﬀectof90μ/kgIVbolusofrVIIaonclotlysistimein
8 healthy volunteers when added to 10mg of fondaparinux
was also studied by Lisman et al. In this study, the authors
found a decrease in the clot lysis time on addition of
fondaparinux (control 80 ± 13 minutes, fondaparinux 65 ±
15 minutes; mean ± SD, P<0.001), and on addition of
rVIIa to fondaparinux-anticoagulated plasma in this group,
a signiﬁcant increase in clot lysis time was observed (from
65±15 minutes to 72±13 minutes, P<0.01), and this eﬀect
lasted for up to 8 hours. The authors concluded that rVIIa
may be an alternative option for reversal of bleeding due to
fondaparinux [65].
Gerotziafas and his colleagues have concluded that
recombinant factor VII (rFVIIa) partially reverses the eﬀect
of fondaparinux on inhibition of thrombin generation. In
theirstudy,theeﬀectofconcentrationsoffondaparinuxfrom
0 . 1t o1 . 0 μg/mL (concentrations required for prophylaxis
and treatment of VTE) and the inﬂuence of rVIIa at 1μg/mL
on various parameters such as lag time (minutes), thrombin
Cmax (nM), Tmax (minutes), and ETP (nM × minutes)
were studied. In the presence of fondaparinux 0.5μg/mL
rVIIa, both the lag time and Tmax of thrombin generation
were decreased by 1 minute. At 0.8μg/mL to 1.0μg/mL of
fondaparinux, rVIIa reduced the lag time by 3 ± 1.5m i n u t e s
and the Tmax of thrombin generation by 4 ± 2m i n u t e s
(P<0.05). The addition of rVIIa to 0.5μg/mL or lower
concentration of fondaparinux did not modify the Cmax and
E T P ,b u ta tc o n c e n t r a t i o n so f0 . 8 μg/mL of fondaparinux,
rVIIa slightly increased Cmax and ETP (63 ± 15nM) and
(840 ±330nM × minutes) (P>0.05) [66].
Ac a s eo fr V I I a( 9 0μg/kg) to a 76-year-old patient who
was on fondaparinux (7.5mg) following head trauma due
to falls has been described in the literature. The patient
received the dose of rVIIa prior to craniotomy for evacuation
of a cranial hematoma; however, the patient did not survive
the trauma due to increasing intracranial pressure following
craniotomy [67].
In another case report of posthip replacement bleeding
following fondaparinux use, rVIIa (90μg/kg), tranexamic
acid (15mg/kg), and transfusion of packed red blood cells
successfullystabilizedhemoglobinlevels[68].Arecentmeta-
analysis reported the safety of rVIIa in randomized clinical
trials. Levi et al. reported higher rates of arterial events
(mostly acute coronary syndrome) in patients who received
rVIIa than in patients who received a placebo (5.5% versus
3.2%; OR: 1.68, 95% CI: 1.20% to 2.36%, P = 0.003).
This diﬀerence was signiﬁcant in patients ≥65 years (9%
versus 3.8%; OR: 2.43, 95% CI: 1.34% to 4.41%, P =
0.003). The dose of rVIIa (80 to 120μg/kg) was also a
signiﬁcant covariate for arterial embolic events in patients
who received rVIIa for central nervous system bleeding (P =
0.02) [69]. The cost of rVIIa use in treatment of minor-to-
moderate bleeding events in patients with hemophilia has
been reported to be $30,818.00 [70]. The use of rVIIa in
bleeding episodes associated with fondaparinux should be
done with caution given the cost, risk of thrombotic events,
and partial reversibility.
3.Idraparinux
Idraparinux, another long-acting factor Xa inhibitor (2.5mg
SQ weekly dose), currently is being investigated in clinical
trial for the prevention and treatment of VTE. Idraparinux
has a longer t1/2 (up to 60 days) and has no antidote
(Table 2)[ 17, 18]. The van Gogh trial showed noninferiority
of idraparinux versus standard of care (UFH with VKA)
for VTE treatment (2.9% versus 3.0%;OR: 0.98, 95% CI:
0.63% to 1.50%). Major bleeding events in the idraparinux
group versus standard-of-care group were 4.5% versus 7.0%
(P = 0.004). In the PE arm of the study, the rate of
recurrent PE in the idraparinux versus standard of care
was 3.5% versus 1.6% (OR: 2.14, 95% CI: 1.21% to
3.78%), which did not meet the noninferiority criteria [71].
Recurrent VTE in six-month subgroup analysis of cancer
patients enrolled in of the van Gogh trial was 2.5% in the
idraparinux group compared to 6.4% in the standard of
care group (hazard ration 0.39, 95%CI: 0.14–1.11). The rate
of bleeding was comparable (OR 0.89, 95% CI: 0.50–1.59)
[72]. These results need further investigation in forthcoming
idraparinux trials. Currently, one case report of successful
reversal of idraparinux with rVIIa (30μg/kg) exists in the
literature [73]. The role of idraparinux in cancer patients
undergoing surgical procedures also needs to be investigated.
Shorter acting anticoagulants such as heparins should be
used in surgical settings where epidurals are indicated.
4.Idrabiotaparinux
Idrabiotaparinux is another long-acting factor Xa inhibitor
(3.0mg SQ weekly dose) that has a t1/2 of up to 60 days
and has no antidote (Table 2). Addition of a biotin moiety
to the molecule of idraparinux has been shown in animal
studies to be neutralized by avidin (egg protein), an antidote
in bleeding cases. A recent study of treatment of VTE (can-
cer patients comprised ∼5%) comparing idrabiotaparinux10 Advances in Hematology
(3.0mg SQ weekly) versus idraparinux (2.5mg SQ weekly)
for 180 days showed equal factor Xa inhibition, recurrent
VTE of 2.3% versus 3.2% (diﬀerence of −0.9%, 95% CI:
−3.2% to −1.4%), clinically relevant bleeding of 5.2% versus
7.3% (diﬀerence of −2.1%, 95% CI: −5.6% to −1.4%, P =
0.29), and a mortality rate of 1.6% versus 3.2% (diﬀerence
of 1.7%, 95% CI: −3.9% to −0.5%). Three patients in the
idrabiotaparinux group required avidin for planned proce-
dures with favorable outcomes [74]. Overall results showed
the comparative eﬃcacy and safety of idrabiotaparinux to
idraparinux. Further trials are needed to assess safety and
eﬃcacy of this agent in cancer patients.
5. Conclusion
More targeted anticoagulants such as factor Xa inhibitors
are being investigated. To date, fondaparinux has received
FDAapprovalforthepreventionandtreatmentofVTE.Such
long-acting agents provide feasibility and better compliance
than VKA or heparins. Evidence suggests that fondaparinux
should be used in the acute phase of VTE treatment, but
evidence of the eﬃcacy and safety for long-term treatment
is lacking, especially in cancer patients. Monitoring patients
for bleeding, especially those at high risk for bleeding, is
necessary owing to the fact that long-acting agent reversal is
partially possible. Evidence of the newer, longer acting factor
Xa inhibitors such as idraparinux and idrabiotaparinux is
clearly lacking at present.
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